Stockscreener 앱 받기
10.23
1.59%
0.16
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
Analysts Have Lowered Expectations For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Its Latest Results - 富途牛牛
EyePoint Pharmaceuticals Sees Analyst Expectations Lowered After Disappointing Q2 Results - AInvest
How did EYPT's revenue streams evolve in Q4 2024? - AInvest
EyePoint (EYPT) Q2 Revenue Drops 44% - AOL.com
EyePoint Pharma: Clinical Progress Amid Financial Hurdles - AInvest
EyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment - MSN
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
EyePoint Pharmaceuticals (EYPT): Chardan Capital Maintains "Buy" Rating | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected at $6.63 Million - AInvest
EyePoint Pharmaceuticals Reports Q2 2025 Financial Results, Highlights Recent Developments and Milestones - AInvest
EyePoint Pharma Advances DURAVYU Trials Amid Financial Challenges - TipRanks
EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating - TipRanks
EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI - TipRanks
EyePoint Pharmaceuticals (EYPT) Receives Updated Analyst Ratings | EYPT Stock News - GuruFocus
EyePoint reports Q2 EPS (85c), consensus (80c) - TipRanks
Earnings call transcript: Eyepoint Pharmaceuticals Q2 2025 sees revenue miss, stock drops - Investing.com India
EyePoint Pharmaceuticals Drops 10.38% on Q2 Loss, Clinical Progress - AInvest
EyePoint Pharmaceuticals Inc Reports Q2 2025 Earnings: EPS of ($ - GuruFocus
EyePoint Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmol - GuruFocus
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
EyePoint Q2 revenue falls 44%, net loss widens - MarketScreener
EyePoint Pharmaceuticals CEO Reveals Latest Retinal Disease Breakthroughs at Major Ophthalmology Conference - Stock Titan
EyePoint Reports Second Quarter 2025 Financial Results and Highl - GuruFocus
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Prev - GuruFocus
EyePoint Pharmaceuticals Inc expected to post a loss of 80 cents a shareEarnings Preview - TradingView
What drives EyePoint Pharmaceuticals Inc. stock priceTake advantage of unprecedented market momentum - Jammu Links News
What makes EyePoint Pharmaceuticals Inc. stock price move sharplyMaximize portfolio growth with strategic plans - Jammu Links News
What is EyePoint Pharmaceuticals Inc. company’s growth strategyPhenomenal trading returns - Jammu Links News
Does EyePoint Pharmaceuticals Inc. stock perform well during market downturnsMaximize returns with strategic trading plans - Jammu Links News
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025Achieve breakthrough growth with proven strategies - Jammu Links News
Why is EyePoint Pharmaceuticals Inc. stock attracting strong analyst attentionBreakout profit opportunities - Jammu Links News
How volatile is EyePoint Pharmaceuticals Inc. stock compared to the marketFree Stock Market Forecast Reports - Jammu Links News
What catalysts could drive EyePoint Pharmaceuticals Inc. stock higher in 2025Navigate market shifts with confidence - Jammu Links News
Is EyePoint Pharmaceuticals Inc. stock overvalued or undervaluedMassive portfolio appreciation - Jammu Links News
What are EyePoint Pharmaceuticals Inc. company’s key revenue driversAccelerated wealth expansion - Jammu Links News
Is it the right time to buy EyePoint Pharmaceuticals Inc. stockFree Investment Community - Jammu Links News
What analysts say about EyePoint Pharmaceuticals Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate EyePoint Pharmaceuticals Inc. as a “Buy”Rapid wealth creation - Jammu Links News
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD - MSN
EyePoint Pharmaceuticals: Positive Buy Rating Based on Promising Clinical Trials and Market Valuation - AInvest
EyePoint Completes Enrollment for Phase 3 Trials - MSN
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire
EyePoint Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Retinal Disease Pipeline - Stock Titan
EyePoint completes enrollment of LUGANO and LUCIA trials - Modern Retina
Why EyePoint Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Accuracy Alerts for ROI Traders Detected - metal.it
EyePoint Pharmaceuticals Completes LUCIA Study Enrollment Ahead of Schedule, Boosts Investor Confidence - AInvest
EyePoint (EYPT) Completes Enrollment in Key LUCIA Study Ahead of Schedule - GuruFocus
How EyePoint Pharmaceuticals Inc. stock reacts to Fed policy changesWeekly Top Gainers Forecast Watchlist Released - beatles.ru
Can EYPT's Q1 2025 EPS forecast signal a rebound? - AInvest
0.24%
3.39%
자본화:
|
볼륨(24시간):